PUBLISHER: DataM Intelligence | PRODUCT CODE: 1316236
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1316236
Global Pancreatic Cancer Market - 2023-2030
Market Overview
The global pancreatic cancer market reached US$ 2.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.7 billion by 2030. The global Pancreatic Cancer market is expected to exhibit a CAGR of 11.1% during the forecast period (2023-2030).
The pancreas can develop both malignant and non-cancerous tumors, among other growths. Pancreatic ductal adenocarcinoma, the most prevalent form of pancreatic cancer, develops in the cells lining the ducts that remove digestive enzymes from the pancreas. Rarely is pancreatic cancer found in its earliest stages, when it is most treatable. This is due to the fact that symptoms frequently don't appear until the disease has spread to other organs.
Market Dynamics
Active Major Players are Boosting the Global Pancreatic Cancer Market Growth During The Forecast Period
In May 2023, Aitia, a pioneer in the creation and use of "Digital Twins" and Causal AI, joined up with Servier to build new Gemini Digital Twins to aid in the fight against pancreatic cancer. This partnership expands on one that was first announced in 2022 for multiple myeloma.
According to the agreement, Aitia and Servier will collaborate to use Servier's pre-clinical assays, therapeutic creation platforms, and expertise along with Aitia's pancreatic cancer digital twins to focus on translational questions to identify, validate, and attempt to develop novel drug targets and drug candidates in pancreatic cancer. Several novel drug targets will be researched for, developed for, and commercialized by Servier under an exclusive option.
Increasing Research and Development Provide Global Pancreatic Cancer Market Growth Opportunities
In September 2022, 'STarT Pancreas' is the name of a cooperative research agreement between Servier and Oncodesign Precision Medicine (OPM) to find and validate new treatment targets for pancreatic ductal adenocarcinoma.
Two steps are included in the three-year agreement between Servier and Oncodesign Precision Medicine (OPM): using data from the OncoSNIPE clinical trial to jointly build an AI analytical platform, identify targets using that platform, and then experimentally validate the pre-selected targets.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the pancreatic cancer market. Clinical trials for pancreatic cancer and other cancers have also been impacted by the pandemic. For the sake of the security of participants and medical personnel, several studies were momentarily stopped or altered. This has impacted the creation of novel treatments and the accessibility of clinical trial alternatives for people with pancreatic cancer.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the pancreatic cancer market is complex and multifaceted. In the impacted areas, the violence put a strain on the healthcare system and services. It could be necessary to redirect funds that would otherwise be allotted to cancer treatment in order to take care of the conflict's immediate demands. This have an effect on the standard of care and accessibility of healthcare services, particularly pancreatic cancer patients' access to diagnosis, treatment, and supportive care.
Segment Analysis
The global pancreatic cancer market is segmented based on type, distribution channel, end-user, and region.
Chemotherapy Segment is Expected to Hold A Dominant Position in the Market Over the Forecast Period
The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the pancreatic cancer market in 2022. Chemotherapy is typically most successful when two or more medications are administered concurrently (particularly as adjuvant or neoadjuvant therapy). A single medication (often gemcitabine, 5-FU, or capecitabine) may be administered for patients who are not healthy enough for combination therapies.
Gemcitabine, 5-fluorouracil (5-FU), Oxaliplatin, Albumin-bound Paclitaxel (Abraxane), Capecitabine (an oral 5-FU medicine), Cisplatin, and Irinotecan are the most popular medications used for both adjuvant and neoadjuvant chemotherapy.
Geographical Analysis
Increasing Collaborations And Partnerships Among The Key Players, And Advancement In Pancreatic Cancer are Factors Driving The European Region
Europe is expected to account for 32.7% of the pancreatic cancer market. For instance, in March 2023, in order to create tailored micro-interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer, SiSaf Ltd, a business that specializes in RNA delivery and therapies, will work with the University of Leipzig in Germany.
The cooperation will bring together the expertise of the University of Leipzig in miRNA targeting and cancer therapy strategies with SiSaf's work in RNA delivery utilizing its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs).
Competitive Landscape
The major global players in the market include: Myriad Genetics Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Viatris Inc., Boston Scientific Corporation, FUJIFILM Holdings Corporation, and Canon Inc. among others.
Why Purchase the Report?
- To visualize the global pancreatic cancer market segmentation based on the type, distribution channel, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of pancreatic cancer market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global pancreatic cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet By Treatment Type
- 3.2. Snippet by End-user
- 3.3. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising prevalence of pancreatic cancer
- 4.1.2. Restraints
- 4.1.2.1. Side effects associated with therapeutics
- 4.1.3. Opportunity
- 4.1.3.1. Technological advancements
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Treatment Type
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.1.2. Market Attractiveness Index, By Treatment Type
- 9.1.3. Targeted Therapies*
- 9.1.4. Introduction
- 9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.1.6. Chemotherapy
- 9.1.7. Surgery
- 9.1.8. Other Treatments
10. By End-user
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.1.2. Market Attractiveness Index, By End-user
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Home care
- 10.5. Others
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.5.1. U.S.
- 11.2.5.2. Canada
- 11.2.5.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.5.1. Germany
- 11.3.5.2. U.K.
- 11.3.5.3. France
- 11.3.5.4. Italy
- 11.3.5.5. Spain
- 11.3.5.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.5.1. Brazil
- 11.4.5.2. Argentina
- 11.4.5.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.5.1. China
- 11.5.5.2. India
- 11.5.5.3. Japan
- 11.5.5.4. Australia
- 11.5.5.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Product Benchmarking
- 12.3. Company Share Analysis
- 12.4. Key Developments and Strategies
13. Company Profiles
- 13.1. Myriad Genetics Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Pfizer Inc.
- 13.3. Novartis AG
- 13.4. Bristol-Myers Squibb Company
- 13.5. AstraZeneca PLC
- 13.6. Amgen Inc.
- 13.7. Viatris Inc.
- 13.8. Boston Scientific Corporation
- 13.9. Clovis Oncology
- 13.10. GlaxoSmithKline
LIST NOT EXHAUSTIVE
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
